NasdaqCM - Nasdaq Real Time Price USD

Dyadic International, Inc. (DYAI)

1.5200 +0.0300 (+2.01%)
As of 9:56 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Mark A. Emalfarb Founder, CEO, President & Director 874.37k -- 1956
Mr. Doug Pace B.A. Executive Vice President of Business Development -- -- --
Ms. Ana Gómez Rodriguez Secretary of the Board -- -- --

Dyadic International, Inc.

1044 North U.S. Highway One
Suite 201
Jupiter, FL 33477-5094
United States
561 743 8333 https://www.dyadic.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
7

Description

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Corporate Governance

Dyadic International, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 9; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
Dyadic International, Inc. Earnings Call

Related Tickers

DVHGF Devonian Health Group Inc.
0.1689
0.00%
 
SRBCF Sirona Biochem Corp.
0.0520
0.00%
 
EVG.L Evgen Pharma plc
0.8000
0.00%
 
NFX.L Nuformix plc
0.1800
-10.00%
 
RAD.AX Radiopharm Theranostics Limited
0.0460
+2.22%
 
SLRX Salarius Pharmaceuticals, Inc.
0.4990
+3.74%
 
ALA.AX Arovella Therapeutics Limited
0.1200
+4.35%
 
DOMH Dominari Holdings Inc.
2.7000
-0.37%
 
QNCX Quince Therapeutics, Inc.
1.0300
0.00%
 
FRES Fresh2 Group Limited
0.6051
+4.58%